Access & Support

Access and Affordability

AMVUTTRA® is accessible and affordable for most patients, regardless of insurance type

Most patients treated with AMVUTTRA pay $0 out-of-pocket
  • AMVUTTRA is the only ATTR-CM and hATTR-PN treatment that is predominantly covered under the medical benefit
  • Most patients with ATTR-CM and hATTR-PN receive coverage through Medicare
  • Access to AMVUTTRA usually does not require prior authorization for Medicare Fee-for-Service (FFS) Part B
  • Prior authorization may be required for Medicare Advantage patients or patients with commercial insurance

Patient Support Through Alnylam Assist

Alnylam Assist® offers support services for you and your patients, including:

  • AMVUTTRA coverage, prior authorization, coding, reimbursement education, and patient-specific benefit verification
  • Low or no-cost programs for eligible patients,* including copay support, a Patient Assistance Program (PAP), and a Quick Start Program
  • One-on-one support for you and your patients throughout their treatment journey

*Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue any program at any time.

Alnylam Assist®
Alnylam Assist logo

8am-6pm, Monday-Friday

Phone: 1-833-256-2748

Fax: 1-833-256-2747

Learn more: AlnylamAssist.com

Alnylam Assist® brochure

Learn more about patient support available through Alnylam Assist®

Download brochure

How to Get Started with AMVUTTRA

  • Your patients may receive AMVUTTRA through health systems, specialty infusion providers, in the clinic, or in the home†
  • To access helpful resources or to submit a Start Form, visit Alnylam Assist®
  • To learn more, contact your local Alnylam representative

†If covered by the patient's insurance.

Electronic Start Form

Complete and submit the Electronic Start Form online with your patient

Electronic Start Form

‡If you are not able to obtain your patient's signature, an Alnylam Case Manager can follow up with them to obtain their consent.

Downloadable Start Form‡

Print, complete with your patient, and fax the Start Form to 1-833-256-2747

Download Start Form

Up next: Resources

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

In a study of patients with hATTR-PN, the most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

In a study of patients with ATTR-CM, no new safety issues were identified.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Indications

AMVUTTRA® (vutrisiran) is indicated for the treatment of the:

  • cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.
  • polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Reference

  1. Data on file. Alnylam Pharmaceuticals, Inc.